Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists

Hazel H. Szeto, Jerry L. Lovelace, Genevieve Fridland, Yi Soong, Joseph Fasolo, Dunli Wu, Dominic M. Desiderio and Peter W. Schiller
Journal of Pharmacology and Experimental Therapeutics July 2001, 298 (1) 57-61;
Hazel H. Szeto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jerry L. Lovelace
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Genevieve Fridland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Soong
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Fasolo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dunli Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominic M. Desiderio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter W. Schiller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Recent evidence suggests that highly selective μ-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-d-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-d-Arg-Phe-Lys-NH2([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the μ-opioid receptor (Kiδ/Kiμ> 10,000) compared with H-Tyr-d-Ala-Gly-MePhe-Gly-ol (DAMGO). In addition, [Dmt1]DALDA was 3000-fold more potent than morphine when administered intrathecally. A potential problem with peptide analogs as therapeutic agents is their susceptibility to enzymatic degradation in vivo and short elimination half-lives. In this study, we compared the stability of DAMGO, DALDA, and [Dmt1]DALDA after systemic administration in sheep. Peptide concentrations were measured using high performance liquid chromatography-mass spectrometry. When incubated in sheep blood at 37°C, DAMGO, DALDA, and [Dmt1]DALDA were stable over 2 h. When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume. Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively. The half-lives of DALDA and [Dmt1]DALDA are even longer than morphine or meperidine in sheep. These favorable pharmacokinetic properties of DALDA and [Dmt1]DALDA, together with their μ-selectivity, potency, and long duration of action, make them ideal candidates as opioid analgesics.

Footnotes

  • This work was supported, in part, by a multicenter program project grant from the National Institute on Drug Abuse (5PO1 DA08924).

  • Abbreviations:
    DAMGO
    H-Tyr-d-Ala-Gly-MePhe-Gly-ol
    DALDA
    H-Tyr-d-Arg-Phe-Lys-NH2
    [Dmt1]DALDA
    H-Dmt-d-Arg-Phe-Lys-NH2
    Dmt
    2′,6′-dimethyltyrosine
    DPDPE
    H-Tyr-c[d-Pen-Gly-Phe-d-Pen]-OH
    MS
    mass spectrometry
    CL
    clearance
    • Received November 21, 2000.
    • Accepted March 13, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 298 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 298, Issue 1
1 Jul 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists

Hazel H. Szeto, Jerry L. Lovelace, Genevieve Fridland, Yi Soong, Joseph Fasolo, Dunli Wu, Dominic M. Desiderio and Peter W. Schiller
Journal of Pharmacology and Experimental Therapeutics July 1, 2001, 298 (1) 57-61;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

In Vivo Pharmacokinetics of Selective μ-Opioid Peptide Agonists

Hazel H. Szeto, Jerry L. Lovelace, Genevieve Fridland, Yi Soong, Joseph Fasolo, Dunli Wu, Dominic M. Desiderio and Peter W. Schiller
Journal of Pharmacology and Experimental Therapeutics July 1, 2001, 298 (1) 57-61;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Transport Is Not Rate-Limiting in Morphine Glucuronidation in the Single-Pass Perfused Rat Liver Preparation
  • Enhanced Hepatic Uptake and Bioactivity of Type α1(I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol
  • Characterization of P-glycoprotein Inhibition by Major Cannabinoids from Marijuana
Show more ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics